BRUSSELS, Belgium I July 24, 2025 I Precirix, a clinical-stage biopharmaceutical company focused on developing innovative targeted radiopharmaceutical ...

LONDON, UK I July 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced the approval of Blenrep in the European Union (EU) for the treatment of adults with ...

Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I), ...

GAITHERSBURG, MD, USA I July 24, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic ...

NEW YORK, NY, USA I July 24, 2025 I GNT Pharma, a late-stage biopharmaceutical company with operations in Seoul and New York, today announced its IND ...

PARIS, France I July 24, 2025 I Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable ...

SCHLIEREN / ZURICH, Switzerland I July 25, 2025 I Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior ...

PARIS, France I July 25, 2025 I Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 19, ...

STUTTGART, Germany I July 24, 2025 I La Merie Publishing released its newest product entitled: Folate Receptor alpha (FRα) Targeted Therapy: a Competitor ...

Antibodies Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalised myasthenia ...

HONG KONG, China I July 23, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial ...

First-in-class Flare platform designed to address targeting and resistance mechanisms in solid tumors to expand curative potential of immunotherapies for ...